

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3426594

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
ECR PHARMACEUTICALS CO., INC.	07/01/2015
PRECISION DERMATOLOGY, INC.	07/01/2015
RECEIVING PARTY DATA	
Name:	BARCLAYS BANK PLC, AS COLLATERAL AGENT
Street Address:	745 SEVENTH AVENUE
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10019
PROPERTY NUMBERS Total: 29	
Property Type	Number
Patent Number:	7790201
Patent Number:	8377480
Patent Number:	8592380
Patent Number:	9018236
Patent Number:	8623330
Patent Number:	8652443
Patent Number:	8784780
Patent Number:	8975295
Patent Number:	7378405
Patent Number:	7981877
Patent Number:	8389502
Patent Number:	8546364
Application Number:	14193482
Application Number:	13803407
Application Number:	13803433
Application Number:	12713379
Application Number:	61152022
Application Number:	14164832
Application Number:	13249960

PATENT

Property Type	Number
Application Number:	13667209
Application Number:	13778696
Application Number:	13313468
Application Number:	11464100
Application Number:	13409608
Application Number:	13937605
Application Number:	14193066
Application Number:	14104074
Application Number:	13343906
Application Number:	14159767

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: marina.kelly@thomsonreuters.com

Correspondent Name: ELAINE CARRERA, LEGAL ASSISTANT

Address Line 1: 80 PINE STREET

Address Line 2: C/O CAHILL GORDON & REINDEL LLP

Address Line 4: NEW YORK, NEW YORK 10005

NAME OF SUBMITTER:	ELAINE CARRERA, LEGAL ASSISTANT
SIGNATURE:	/Marina Kelly, Thomson Reuters/
DATE SIGNED:	07/06/2015

Total Attachments: 15

source=US - Patent Security Agreement 15#page1.tif
source=US - Patent Security Agreement 15#page2.tif
source=US - Patent Security Agreement 15#page3.tif
source=US - Patent Security Agreement 15#page4.tif
source=US - Patent Security Agreement 15#page5.tif
source=US - Patent Security Agreement 15#page6.tif
source=US - Patent Security Agreement 15#page7.tif
source=US - Patent Security Agreement 15#page8.tif
source=US - Patent Security Agreement 15#page9.tif
source=US - Patent Security Agreement 15#page10.tif
source=US - Patent Security Agreement 15#page11.tif
source=US - Patent Security Agreement 15#page12.tif
source=US - Patent Security Agreement 15#page13.tif
source=US - Patent Security Agreement 15#page14.tif
source=US - Patent Security Agreement 15#page15.tif

PATENT SECURITY AGREEMENT

This **PATENT SECURITY AGREEMENT**, dated as of July 1, 2015 (as it may be amended, restated, supplemented or otherwise modified from time to time, this “**Agreement**”), is made by the entities identified as grantors on the signature pages hereto (collectively, the “**Grantors**”) in favor of Barclays Bank PLC, as collateral agent for the Secured Parties (in such capacity, together with its successors and permitted assigns, the “**Collateral Agent**”).

WHEREAS the Grantor is subject to, and is made party to, the Pledge and Security Agreement, dated as of June 29, 2011, as amended by the Amended and Restated Pledge and Security Agreement, dated as of October 20, 2011, and as further amended by the Second Amended and Restated Pledge and Security Agreement, dated as of February 13, 2012 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Pledge and Security Agreement**”) between each of the Grantors and the other grantors party thereto and the Collateral Agent pursuant to which the Grantors granted a security interest to the Collateral Agent in the Patent Collateral (as defined below) and are required to execute and deliver this Agreement.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors hereby agree with the Collateral Agent as follows:

SECTION. 1. Defined Terms

Unless otherwise defined herein, terms defined in the Pledge and Security Agreement and used herein have the meaning given to them in the Pledge and Security Agreement.

SECTION 2. Grant of Security Interest

Each Grantor hereby grants to the Collateral Agent, for the benefit of the Secured Parties, a security interest in and continuing lien on all of such Grantor’s right, title and interest in, to and under the following, in each case whether now owned or hereafter acquired by such Grantor or in which any Grantor now has or hereafter acquires any right, title or interest and wherever the same may be located (collectively, the “**Patent Collateral**”):

all United States and foreign patents and certificates of invention, or similar industrial property rights, and applications for any of the foregoing, including, but not limited to: (i) each patent and patent application listed in Schedule A attached hereto, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations thereof, (iii) all patentable inventions and improvements thereto, (iv) the right to sue or otherwise recover for any past, present and future infringement or other violation thereof, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit now or hereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing there- under or pertaining thereto throughout the world, but in any case excluding any Excluded Assets.

SECTION 3. Security Agreement

The security interest granted pursuant to this Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the Secured Parties pursuant to the Pledge and Security Agreement, and the Grantors hereby acknowledge and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Patent Collateral made and granted hereby are

more fully set forth in the Pledge and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Agreement is deemed to conflict with the Pledge and Security Agreement, the provisions of the Pledge and Security Agreement shall control.

SECTION 4. Governing Law

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.


SECTION 5. Counterparts

This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.


[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

ECR PHARMACEUTICALS CO., INC.

By: 
Name: Linda A. LaGorga
Title: Treasurer

PRECISION DERMATOLOGY, INC.

By: 
Name: Linda A. LaGorga
Title: Senior Vice President, Treasurer

[Signature Page to Patent Security Agreement]

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Accepted and Agreed:

BARCLAYS BANK PLC,

as Collateral Agent

By: 

Name:

Title: **Craig Malloy**

Director

[Signature Page to Patent Security Agreement]

SCHEDULE A
to
PATENT SECURITY AGREEMENT

PATENTS AND PATENT APPLICATIONS

ECR PHARMACEUTICALS CO., INC. PATENT SCHEDULE

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
United States	GRANULAR SUSTAINED RELEASE PREPARATION AND PRODUCTION THEREOF	10/570,242	2/28/2006	7790201	9/7/2010	ECR Pharmaceuticals Co. Inc.
United States	GRANULAR SUSTAINED RELEASE PREPARATION AND PRODUCTION THEREOF	12/850,087	8/4/2010	8377480	2/19/2013	ECR Pharmaceuticals Co. Inc.

PRECISION DERMATOLOGY, INC. PATENT SCHEDULE

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
CANADA	AEROSOL FOAMS COMPRISING CLINDAMYCIN PHOSPHATE	2,794,503	3/22/2011	2,794,503	9/29/2011	Precision Dermatology, Inc.
EUROPE	AEROSOL FOAMS COMPRISING CLINDAMYCIN PHOSPHATE	11760052.8	3/22/2011	2563336	3/6/2013	Precision Dermatology, Inc.
WIPO	AEROSOL FOAMS COMPRISING CLINDAMYCIN	PCT/US11/29390	3/22/2011	119585	9/29/2011	Precision Dermatology, Inc.

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
	PHOSPHATE					
United States	AEROSOL FOAMS COMPRISING CLINDAMYCIN PHOSPHATE	13/053,524	3/22/2011	8,592,380	11/26/2013	Precision Dermatology, Inc.
United States	CONTROLLING THE BIOAVAILABILITY OF ACTIVE INGREDIENTS IN TOPICAL FORMULATIONS	14/193,482	2/28/2014			Precision Dermatology, Inc.
WIPO	CONTROLLING THE BIOAVAILABILITY OF ACTIVE INGREDIENTS IN TOPICAL FORMULATIONS	PCT/US14/19378	2/28/2014			Precision Dermatology, Inc.
AUSTRALIA	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	2013235483	3/14/2013			Precision Dermatology, Inc.
BRAZIL	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	PCT/US13/31296	3/14/2013			Precision Dermatology, Inc.
CANADA	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	PCT/US13/31296	3/14/2013			Precision Dermatology, Inc.
CHINA	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	PCT/US13/31296	3/14/2013			Precision Dermatology, Inc.
EUROPE	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	PCT/US13/31296	3/14/2013			Precision Dermatology, Inc.

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
JAPAN	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	PCT/US13/31296	3/14/2013			Precision Dermatology, Inc.
MEXICO	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	MX/a/2014/011181	3/14/2013			Precision Dermatology, Inc.
SOUTH KOREA	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	PCT/US13/31296	3/14/2013			Precision Dermatology, Inc.
United States	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	13/803,280	3/14/2013	9,018,236	4/28/25015	Precision Dermatology, Inc.
United States	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	13/803,407	3/14/2013			Precision Dermatology, Inc.
United States	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	13/803,433	3/14/2013			Precision Dermatology, Inc.
WIPO	CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF	PCT/US13/31296	3/14/2013			Precision Dermatology, Inc.
CANADA	EMOLLIENT FOAMS FOR TREATMENT OF DERMATOSES	2,791,014	3/17/2010			Precision Dermatology, Inc.
EUROPE	EMOLLIENT FOAMS FOR TREATMENT OF DERMATOSES	10846778.8	3/17/2010			Precision Dermatology, Inc.

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
JAPAN	EMOLLIENT FOAMS FOR TREATMENT OF DERMATOSES	PCT/US10/27615	3/17/2010			Precision Dermatology, Inc.
MEXICO	EMOLLIENT FOAMS FOR TREATMENT OF DERMATOSES	MX/a/2012/009842	8/24/2012			Precision Dermatology, Inc.
WIPO	EMOLLIENT FOAMS FOR TREATMENT OF DERMATOSES	PCT/US10/27615	3/17/2010			Precision Dermatology, Inc.
United States	EMOLLIENT FOAMS FOR TREATMENT OF DERMATOSES	12/713,379	2/26/2010			Precision Dermatology, Inc.
WIPO	EMOLLIENT FOAMS FOR TREATMENT OF SEBORRHEIC DERMATITIS	PCT/US11/23178	1/31/2011			Precision Dermatology, Inc.
United States	EMOLLIENT FOAMS FOR TREATMENT OF SEBORRHEIC DERMATITIS	13/017,204	1/31/2011	8,623,330	1/7/2014	Precision Dermatology, Inc.
WIPO	FOAMABLE BENZOYL PEROXIDE COMPOSITIONS FOR TOPICAL ADMINISTRATION	PCT/US09/54752	8/24/2009			Precision Dermatology, Inc.
United States	FOAMABLE BENZOYL PEROXIDE COMPOSITIONS FOR TOPICAL ADMINISTRATION	61/152,022	2/12/2009			Precision Dermatology, Inc.
CANADA	FOAMABLE BENZOYL PEROXIDE COMPOSITIONS FOR TOPICAL ADMINISTRATION	2752070	8/24/2009			Precision Dermatology, Inc.
EUROPE	FOAMABLE BENZOYL PEROXIDE COMPOSITIONS FOR TOPICAL ADMINISTRATION	09840157.3	8/24/2009			Precision Dermatology, Inc.

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
MEXICO	FOAMABLE BENZOYL PEROXIDE COMPOSITIONS FOR TOPICAL ADMINISTRATION	MX/a/2011/008273	8/5/2011			Precision Dermatology, Inc.
United States	FOAMABLE BENZOYL PEROXIDE COMPOSITIONS FOR TOPICAL ADMINISTRATION	14/164,832	1/27/2014			Precision Dermatology, Inc.
WIPO	FOAMABLE MICROEMULSION COMPOSITIONS FOR TOPICAL ADMINISTRATION	PCT/US10/22375	1/28/2010			Precision Dermatology, Inc.
MEXICO	FOAMABLE MICROEMULSION COMPOSITIONS FOR TOPICAL ADMINISTRATION	MX/a/2011/008266	8/5/2011			Precision Dermatology, Inc.
United States	FOAMABLE MICROEMULSION COMPOSITIONS FOR TOPICAL ADMINISTRATION	12/371,155	2/13/2009	8,652,443	2/18/2014	Precision Dermatology, Inc.
EUROPE	HIGH OIL-CONTENT EMOLLIENT AEROSOL FOAM COMPOSITIONS	11792808.5	3/11/2011			Precision Dermatology, Inc.
JAPAN	HIGH OIL-CONTENT EMOLLIENT AEROSOL FOAM COMPOSITIONS	PCT/US11/28079	3/11/2011			Precision Dermatology, Inc.
WIPO	HIGH OIL-CONTENT EMOLLIENT AEROSOL FOAM COMPOSITIONS	PCT/US11/28079	3/11/2011			Precision Dermatology, Inc.
United States	HIGH OIL-CONTENT EMOLLIENT AEROSOL FOAM COMPOSITIONS	13/046,088	3/11/2011	8,784,780	7/22/2014	Precision Dermatology, Inc.

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
United States	METHOD AND SYSTEM FOR AUTOMATIC PRODUCT REPLENISHMENT	13/249,960	9/30/2011			Precision Dermatology, Inc.
AUSTRALIA	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	2003284337	10/22/2003	2003284337	7/29/2010	Precision Dermatology, Inc.
BRAZIL	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	P10315649-4	10/22/2003			Precision Dermatology, Inc.
CANADA	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	2503492	10/22/2003	2,503,489	9/10/2013	Precision Dermatology, Inc.
EUROPE	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	03776519.5	10/22/2003			Precision Dermatology, Inc.
HONG KONG	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	06104438.6	12/4/2006			Precision Dermatology, Inc.
WIPO	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	PCT/US03/33598	10/22/2003			Precision Dermatology, Inc.
United States	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	10/692,191	10/22/2003	8,975,295	3/10/2015	Precision Dermatology, Inc.
SOUTH AFRICA	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	2005/03253	4/21/2005	2005/03253	7/26/2006	Precision Dermatology, Inc.
SOUTH KOREA	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	2011-7031695	10/22/2003			Precision Dermatology, Inc.
SOUTH KOREA	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	2013-7013437	10/22/2003			Precision Dermatology, Inc.

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
SINGAPORE	MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES	201108812-7	10/22/2003			Precision Dermatology, Inc.
United States	STABILIZED STEROID COMPOSITION AND METHOD FOR ITS PREPARATION	10/762,652	1/22/2004	7,378,405	5/27/2008	Precision Dermatology, Inc.
United States	STABILIZED STEROID COMPOSITION AND METHOD FOR ITS PREPARATION	11/432,742	5/11/2006	7,981,877	7/19/2011	Precision Dermatology, Inc.
United States	STABILIZED STEROID COMPOSITION AND METHOD FOR ITS PREPARATION	13/155,493	6/8/2011	8,389,502	3/5/2013	Precision Dermatology, Inc.
United States	STABILIZED STEROID COMPOSITION AND METHOD FOR ITS PREPARATION	12/840,487	7/21/2010	8,546,364	10/1/2013	Precision Dermatology, Inc.
CANADA	STABLE DERMATOLOGICAL AEROSOL FOAMS UTILIZING REACTIVE PROPELLANTS	2,854,449	11/2/2012			Precision Dermatology, Inc.
EUROPE	STABLE DERMATOLOGICAL AEROSOL FOAMS UTILIZING REACTIVE PROPELLANTS	12844822.2	11/2/2012			Precision Dermatology, Inc.
JAPAN	STABLE DERMATOLOGICAL AEROSOL FOAMS UTILIZING REACTIVE PROPELLANTS	2014-540114	11/2/2012			Precision Dermatology, Inc.
WIPO	STABLE DERMATOLOGICAL AEROSOL FOAMS UTILIZING REACTIVE PROPELLANTS	PCT/US12/63188	11/2/2012			Precision Dermatology, Inc.
United States	STABLE DERMATOLOGICAL AEROSOL FOAMS UTILIZING REACTIVE PROPELLANTS	13/667,209	11/2/2012			Precision Dermatology, Inc.
United States	STABLE, NON-IRRITATING TOPICAL FORMULATIONS OF HYDROQUINONE	13/778,696	2/27/2013			Precision Dermatology, Inc.

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
United States	TANDEM HYPOCHLORITE-BARRIER REPAIR THERAPY FOR THE TREATMENT OF ECZEMA	13/313,468	12/7/2011			Precision Dermatology, Inc.
CANADA	TOPICAL AEROSOL FOAMS	2528818	10/4/2004	2528818	8/10/2010	Precision Dermatology, Inc.
WIPO	TOPICAL AEROSOL FOAMS	PCT/US04/32714	10/4/2004			Precision Dermatology, Inc.
WIPO	TOPICAL DELIVERY WITH A CARRIER FLUID	PCT/US06/031648	8/11/2006			Precision Dermatology, Inc.
United States	TOPICAL DELIVERY WITH A CARRIER FLUID	11/464,100	8/11/2006			Precision Dermatology, Inc.
United States	TOPICAL DELIVERY WITH A CARRIER FLUID	13/409,608	3/1/2012			Precision Dermatology, Inc.
United States	TOPICAL FORMULATIONS COMPRISING DNA REPAIR ENZYMES, AND METHODS OF USE THEREOF	13/937,605	7/9/2013			Precision Dermatology, Inc.
WIPO	TOPICAL FORMULATIONS COMPRISING DNA REPAIR ENZYMES, AND METHODS OF USE THEREOF	PCT/US13/49681	7/9/2013			Precision Dermatology, Inc.
WIPO	TOPICAL FORMULATIONS FOR INCREASING THE DERMAL CONCENTRATION OF HYALURONIC ACID	PCT/US13/74711	12/12/2013			Precision Dermatology, Inc.
United States	TOPICAL FORMULATIONS OF CORTICOSTEROIDS WITH ENHANCED BIOAVAILABILITY	14/193,066	2/28/2014			Precision Dermatology, Inc.
WIPO	TOPICAL FORMULATIONS OF CORTICOSTEROIDS WITH ENHANCED BIOAVAILABILITY	PCT/US14/19248	2/28/2014			Precision Dermatology, Inc.

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
United States	TOPICAL FORMULATIONS FOR INCREASING THE DERMAL CONCENTRATION OF HYALURONIC ACID	14/104,074	12/12/2013			Precision Dermatology, Inc.
SWITZERLAND	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	06817315.2	10/24/2006	1948130	9/11/2013	Precision Dermatology, Inc.
GERMANY	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	06817315.2	10/24/2006	1948130	9/11/2013	Precision Dermatology, Inc.
EUROPE	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	06817315.2	10/24/2006	1948130	9/11/2013	Precision Dermatology, Inc.
FRANCE	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	06817315.2	10/24/2006	1948130	9/11/2013	Precision Dermatology, Inc.
UNITED KINGDOM	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	06817315.2	10/24/2006	1948130	9/11/2013	Precision Dermatology, Inc.
ITALY	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	06817315.2	10/24/2006	1948130	9/11/2013	Precision Dermatology, Inc.
WIPO	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	PCT/US06/41366	10/24/2006			Precision Dermatology, Inc.
United States	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	13/343,906	1/5/2012			Precision Dermatology, Inc.
United States	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	14/159,767	1/21/2014			Precision Dermatology, Inc.
SWITZERLAND	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	09162106	10/24/2006	2100601	6/27/2012	Precision Dermatology, Inc.
GERMANY	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	09162106	10/24/2006	2100601	6/27/2012	Precision Dermatology, Inc.
EUROPE	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	09162106	10/24/2006	2100601	6/27/2012	Precision Dermatology, Inc.
FRANCE	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	09162106	10/24/2006	2100601	6/27/2012	Precision Dermatology, Inc.
UNITED KINGDOM	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	09162106	10/24/2006	2100601	6/27/2012	Precision Dermatology, Inc.
ITALY	TOPICAL PHARMACEUTICAL FOAM COMPOSITION	09162106	10/24/2006	2100601	6/27/2012	Precision Dermatology, Inc.

Jurisdiction	Title	Application No.	Application Date	Patent No.	Grant Date	Owner
WIPO	TOPICAL TREATMENT OF LOCALIZED SCLERODERMA	PCT/US14/40189	5/30/2014			Precision Dermatology, Inc.

PATENT

REEL: 036091 FRAME: 0272

RECORDED: 07/06/2015